表紙
市場調查報告書

降壓劑的全球市場:2023

Antihypertensives: Global Markets to 2023

出版商 BCC Research 商品編碼 778292
出版日期 內容資訊 英文 144 Pages
訂單完成後即時交付
價格
降壓劑的全球市場:2023 Antihypertensives: Global Markets to 2023
出版日期: 2019年01月24日內容資訊: 英文 144 Pages
簡介

預計全球降壓劑的市場規模,預計將從2018年的263億美元,到2023年達278億美元,並以1.1%的年複合成長率 (CAGR) 成長。

本報告提供全球降壓劑市場相關調查分析,主要國家的資料與分析,市場現狀及未來的可能性及競爭環境分析,政府法規及技術更新,法規動態,開發平台分析,專利分析,市場成長的推動要素、阻礙因素機會,及主要企業簡介等資訊彙整。

第1章 簡介

第2章 摘要和亮點

第3章 技術、市場背景

  • 高血壓
  • 降壓劑
  • 頑固性高血壓

第4章 市場動態

  • 市場成長的推動要素
  • 市場成長的阻礙因素
  • 市場機會

第5章 市場分析:各類藥物

  • 全球降壓劑市場
  • 血管收縮素轉化酵素 (ACE) 抑制劑
  • 血管收縮素II受體拮抗劑 (ARB)
  • β受體阻斷劑
  • 鈣拮抗劑
  • 利尿劑
  • 複合藥
  • 其他

第6章 市場分析:各地區

  • 全球降壓劑市場:各地區
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第7章 法規環境

  • 美國的法規
  • 歐洲的法規
  • 亞太地區的法規

第8章 專利分析

第9章 開發平台分析

第10章 競爭情形

第11章 企業簡介

  • ALLERGAN PLC
  • ASTELLAS PHARMA INC.
  • ARBOR PHARMACEUTICALS LLC
  • ASTRAZENECA PLC
  • BAYER AG
  • BOEHRINGER INGELHEIM GMBH
  • 第一三共
  • ELI LILLY AND CO.
  • GILEAD SCIENCES INC.
  • GLAXOSMITHKLINE PLC
  • HIKMA PHARMACEUTICALS PLC
  • JOHNSON & JOHNSON
  • LUPIN LTD.
  • MERCK & CO. INC.
  • NOVARTIS AG
  • PFIZER INC.
  • SANOFI
  • 武田藥品工業
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • UNITED THERAPEUTICS CORP.

第12章 附錄:縮寫

目錄
Product Code: HLC159A

Report Highlights:

The global market for antihypertensive drugs should grow from nearly $26.3 billion in 2018 to $27.8 billion by 2023 with a compound annual growth rate (CAGR) of 1.1% for the period of 2018-2023.

Combination drugs market should grow from $5.7 billion in 2018 to nearly $6.1 billion by 2023 with a CAGR of 1.4% for the period of 2018-2023.

ARBs (Angiotensin II receptor blockers) market should grow from nearly $4.9 billion in 2018 to nearly $5.1 billion by 2023 with a CAGR of 1.0% for the period of 2018-2023.

Report Scope:

The current report offers a detailed analysis of the antihypertensive drug market. The study includes a discussion of antihypertensive drugs prescribed for lowering the high blood pressure and for the treatment of pulmonary arterial hypertension (PAH). The report excludes drugs used in the treatment of ocular hypertension. The market size includes both branded and generic drugs.

The report highlights the current and future market potential of antihypertensive drugs and provides a detailed analysis of the competitive environment, regulatory scenario, patent analysis, pipeline analysis, drivers, restraints, opportunities and trends in the market. The report also covers market projections through 2023, as well as market shares for key market players.

The report details market shares of antihypertensive drugs based on drug class and geography. Based on drug class, the market is segmented into ACE inhibitors (angiotensin-converting enzyme inhibitors), ARBs (angiotensin II receptor blockers), beta blockers, calcium channel blockers, diuretics, combination drugs, and others (a segment that includes direct renin inhibitors, alpha blockers, PDE-5 inhibitors, stimulators of soluble guanylate cyclase, endothelin receptor antagonists, vasodilators, and prostacyclin receptors).

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Spain, Italy, Japan, China and India. For market estimates, data is provided for 2017 as the base year, with forecasts for 2018 through 2023. Estimated values are based on drug manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Report Includes:

  • 67 tables
  • Country specific data and analysis for France, Germany, Italy, U.K., Spain, Russia, India, China, Japan, United States, Canada, Middle East and Africa
  • A brief study of current and future market potential of antihypertensive drugs along with a detailed analysis of the competitive environment
  • Exposure to the industry driven underlying markets, government regulations, and technology updates
  • Coverage of regulatory dynamics, pipeline analysis, patent analysis, and market drivers, restrains, and opportunities
  • Company profiles of major manufacturers, suppliers, and supply chain participants, including Allergan Plc, Boehringer Ingelheim GMBH, Johnson & Johnson, Daiichi Sankyo Co. Ltd, Pfizer Inc. and Novartis AG

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analysts' Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

  • Hypertension
    • Pathophysiology and Pathogenesis
    • Classification
    • Prevalence of Hypertension
  • Antihypertensive Drugs
    • Commonly Prescribed Antihypertensive Drugs
    • Side Effects of Antihypertensive Drugs
    • Contraindications of Major Antihypertensive Drugs
  • Resistant Hypertension

Chapter 4: Market Dynamics

  • Growth Drivers
    • Increasing Prevalence of Hypertension
    • Rising Geriatric Population and Government Assistance for Prescription Drugs
    • Sedentary Lifestyle: Contributing Significantly toward High Risk of Hypertension
    • Improved Awareness of Hypertension: Earlier Diagnosis and Treatment
  • Market Restraints
    • Patent Expirations of Branded Drugs
    • Drug Development Process: High Cost and Pricing Pressures
  • Market Opportunities
    • Patent Expiration: Growth Opportunities for Generic Players
    • Unmet Needs in Low- and Middle-Income Countries

Chapter 5: Market Breakdown by Drug Class

  • Global Antihypertensive Drug Market
  • Angiotensin-Converting Enzyme (ACE) Inhibitors
    • Market Size and Forecast
    • Market Analysis
  • Angiotensin II Receptor Blockers
    • Market Size and Forecast
    • Market Analysis
  • Beta Blockers
    • Market Size and Forecast
    • Market Analysis
  • Calcium Channel Blockers
    • Market Size and Forecast
    • Market Analysis
  • Diuretics
    • Market Size and Forecast
    • Market Analysis
  • Combination Drug
    • Market Size and Forecast
    • Market Analysis
  • Others
    • Market Size and Forecast
    • Market Analysis

Chapter 6: Market Breakdown by Region

  • Global Market for Antihypertensives by Region
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • South America
    • Market Size and Forecast
    • Market Analysis
  • Middle East and Africa
    • Market Size and Forecast
    • Market Analysis

Chapter 7: Regulatory Environment

  • Regulations in the U.S.
    • New Drug Approvals
    • The FDA Modernization Act of 1997
    • Fast-Track Status
    • Special Protocol Assessments
    • Medicare
    • Principles for Clinical Evaluation of New Antihypertensive Drugs
    • Hypertension Guidelines in the U.S.
  • Regulations in Europe
    • Hypertension Guidelines in Europe
    • Pricing and Reimbursement
  • Regulations in Asia-Pacific
    • Regulations in Japan
    • Regulations in China
    • Regulations in India

Chapter 8: Patent Analysis

  • Patent Length and Market Exclusivity

Chapter 9: Pipeline Analysis

  • Overview of the Drug Development Process
  • Pipeline Analysis of Antihypertensive Drugs
    • Antihypertensive Drugs in Phase I Clinical Trials
    • Antihypertensive Drugs in Phase II Clinical Trials
    • Antihypertensive Drugs in Phase III Clinical Trials
  • Late-Stage Pipeline Drugs

Chapter 10: Competitive Landscape

  • Global Company Share Analysis
  • Mergers and Acquisitions
  • Agreements, Collaborations, and Partnerships
  • Impact of Generic Antihypertensives on the Market

Chapter 11: Company Profiles

  • ALLERGAN PLC
    • Company Overview
    • Business Performance
    • Products Offered
    • Developments and Strategies
  • ASTELLAS PHARMA INC.
    • Company Overview
    • Products Offered
    • Developments and Strategies
  • ARBOR PHARMACEUTICALS LLC
    • Company Overview
    • Products Offered
  • ASTRAZENECA PLC
    • Company Overview
    • Business Performance
    • AstraZeneca plc Business Segment Revenue
    • AstraZeneca Plc Revenue by Region Segment
    • Product Portfolio
    • Developments and Strategies
  • BAYER AG
    • Company Overview
    • Business Performance
    • Products Offered
    • Developments and Strategies
  • BOEHRINGER INGELHEIM GMBH
    • Company Overview
    • Business Performance
    • Products Offered
    • Developments and Strategies
  • DAIICHI SANKYO CO. LTD.
    • Company Overview
    • Business Performance
    • Products Offered
    • Developments and Strategies
  • ELI LILLY AND CO.
    • Company Overview
    • Products Offered
    • Developments and Strategies
  • GILEAD SCIENCES INC.
    • Company Overview
    • Business Performance
    • Products Offered
    • Developments and Strategies
  • GLAXOSMITHKLINE PLC
    • Company Overview
    • Products Offered
    • Developments and Strategies
  • HIKMA PHARMACEUTICALS PLC
    • Company Overview
    • Products Offered
  • JOHNSON & JOHNSON
    • Company Overview
    • Business Performance
    • Product Portfolio
    • Developments and Strategies
  • LUPIN LTD.
    • Company Overview
    • Product Portfolio
  • MERCK & CO. INC.
    • Company Overview
    • Products Offered
    • Developments and Strategies
  • NOVARTIS AG
    • Company Overview
    • Business Performance
    • Products Offered
    • Developments and Strategies
  • PFIZER INC.
    • Company Overview
    • Business Performance
    • Products Offered
    • Developments and Strategies
  • SANOFI
    • Company Overview
    • Business Performance
    • Products Offered
    • Developments and Strategies
  • TAKEDA PHARMACEUTICAL CO. LTD.
    • Company Overview
    • Product Portfolio
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • Company Overview
    • Products Offered
  • UNITED THERAPEUTICS CORP.
    • Company Overview
    • Business Performance
    • Products Offered
    • Developments and Strategies

Chapter 12: Appendix: Acronyms

List of Tables

  • Summary Table: Global Market for Antihypertensive Drugs, by Drug Class, Through 2023
    • Table 1: Classification of Hypertension or Blood Pressure
    • Table 2: Global Prevalence of Hypertension with Population Aged 18 Years or Older, by Country, 2015
    • Table 3: Commonly Prescribed Antihypertensive Drugs
    • Table 4: Side Effects with Different Classes of Antihypertensive Drugs
    • Table 5: Contraindications of Major Antihypertensive Drugs
    • Table 6: Prevalence of High Blood Pressure, by Gender and Age Group, U.S., 2016
    • Table 7: Prevalence Rates of Obesity for Male and Female in Australia, 1995-2015
    • Table 8: Patent Expiration Dates for Antihypertensive Drugs, 2016-2018*
    • Table 9: Global Market for Antihypertensive Drugs, by Drug Class, Through 2023
    • Table 10: Global Market for Angiotensin-Converting Enzyme (ACE) Inhibitors, by Region, Through 2023
    • Table 11: ACE Inhibitors Drug, Branded/Generic FDA Approval
    • Table 12: Global Market for Angiotensin II Receptor Blockers (ARBs), by Region, Through 2023
    • Table 13: Global Market for Beta Blocker Drugs, by Region, Through 2023
    • Table 14: Global Market for Calcium Channel Blocker Drugs, by Region, Through 2023
    • Table 15: Global Market for Diuretics Drugs, by Region, Through 2023
    • Table 16: Global Market for Combination Drugs, by Region, Through 2023
    • Table 17: Commonly Prescribed Combinations of Antihypertensive Drugs
    • Table 18: Global Market for Other Antihypertensive Drugs, by Region, Through 2023
    • Table 19: Commonly Prescribed Types of Other Antihypertensive Drugs
    • Table 20: Global Market for Antihypertensive Drugs, by Region, Through 2023
    • Table 21: North American Market for Antihypertensive Drugs, by Drug Class, Through 2023
    • Table 22: North American Market for Antihypertensive Drugs, by Country, Through 2023
    • Table 23: Total Number of High Blood Pressure Patients in Canada, by Age Group, 2016 and 2017
    • Table 24: European Market for Antihypertensive Drugs, by Drug Class, Through 2023
    • Table 25: European Market for Antihypertensive Drugs, by Country, Through 2023
    • Table 26: Asia-Pacific Market for Antihypertensive Drugs, by Drug Class, Through 2023
    • Table 27: Asia-Pacific Market for Antihypertensive Drugs, by Country, Through 2023
    • Table 28: South American Market for Antihypertensive Drugs, by Drug Class, Through 2023
    • Table 29: Middle Eastern and African Market for Antihypertensive Drugs, by Drug Class, Through 2023
    • Table 30: Arbor Pharmaceuticals LLC: Antihypertensives Patent Exclusivity
    • Table 31: Allergan Plc: Antihypertensives Patent Exclusivity
    • Table 32: Chiesi USA Inc.: Antihypertensives Patent Exclusivity
    • Table 33: Eli Lilly and Co.: Antihypertensives Patent Exclusivity
    • Table 34: Gilead Sciences Inc.: Antihypertensives Patent Exclusivity
    • Table 35: GlaxoSmithKline plc: Antihypertensives Patent Exclusivity
    • Table 36: Novartis AG: Antihypertensives Patent Exclusivity
    • Table 37: Noden Pharma DAC: Antihypertensives Patent Exclusivity
    • Table 38: Johnson & Johnson: Antihypertensives Patent Exclusivity
    • Table 39: United Therapeutics Corp.: Antihypertensives Patents Exclusivity
    • Table 40: Other Applicants: Antihypertensives Patent Exclusivity
    • Table 41: Exclusivity Expiration of Antihypertensive Drugs
    • Table 42: Preclinical & Phase I Pipeline of Antihypertensive Drugs
    • Table 43: Phase II Pipeline of Antihypertensive Drugs
    • Table 44: Phase III Pipeline of Antihypertensive Drugs
    • Table 45: Generic Launches in the Antihypertensive Market, 2015-2018
    • Table 46: Allergan Plc: Antihypertensive Drugs Product Portfolio
    • Table 47: Astellas Pharma Inc.: Antihypertensive Drugs Product Portfolio
    • Table 48: Arbor Pharmaceutical LLC.: Antihypertensive Drugs Product Portfolio
    • Table 49: AstraZeneca Plc: Antihypertensive Drugs Product Portfolio
    • Table 50: Bayer AG: Antihypertensive Drugs Product Portfolio
    • Table 51: Boehringer Ingelheim GmbH: Antihypertensive Drugs Product Portfolio
    • Table 52: Daiichi Sankyo Co. Ltd.: Antihypertensive Drugs Product Portfolio
    • Table 53: Eli Lilly and Co.: Antihypertensive Drugs Product Portfolio
    • Table 54: Gilead Science Inc.: Antihypertensive Drugs Product Portfolio
    • Table 55: GlaxoSmithKline Plc: Antihypertensive Drugs Product Portfolio
    • Table 56: Hikma Pharmaceuticals Plc: Antihypertensive Drugs Product Portfolio
    • Table 57: Johnson & Johnson: Antihypertensive Drugs Product Portfolio
    • Table 58: Lupin Ltd.: Antihypertensive Drugs Product Portfolio
    • Table 59: Merck & Co. Inc.: Antihypertensive Drugs Product Portfolio
    • Table 60: Novartis AG: Antihypertensive Drugs Product Portfolio
    • Table 61: Pfizer Inc.: Antihypertensive Drugs Product Portfolio
    • Table 62: Sanofi: Antihypertensive Drugs Product Portfolio
    • Table 63: Takeda Pharmaceutical.: Antihypertensive Drugs Product Portfolio
    • Table 64: Teva Pharmaceutical Industries Ltd.: Antihypertensive Drugs Product Portfolio
    • Table 65: United Therapeutics Corp.: Antihypertensive Drugs Product Portfolio
    • Table 66: Acronyms Used in This Report

List of Figures

  • Summary Figure: Global Market Share for Antihypertensive Drugs, by Drug Class, 2017
    • Figure 1: Prevalence of Hypertension Among U.S. Adults Aged 18 and Older, by Sex and Age, 2016
    • Figure 2: Prevalence Rates for Adult Obesity, by Country, 2016
    • Figure 3: Diovan/Co-Diovan Revenue, 2013-2017
    • Figure 4: Global Market Share for Antihypertensive Drugs, by Drug Class, 2017
    • Figure 5: Global Market for Angiotensin-Converting Enzyme (ACE) Inhibitors, 2017-2023
    • Figure 6: Global Market for Angiotensin-Converting Enzyme (ACE) Inhibitors, by Region, 2017-2023
    • Figure 7: Global Market for Angiotensin II Receptor Blockers (ARBs), 2017-2023
    • Figure 8: Global Market for Angiotensin II Receptor Blockers (ARBs), by Region, 2017-2023
    • Figure 9: Leading ARBs Drug Prescriptions in the U.S., 2016
    • Figure 10: Global Market for Beta Blocker Drugs, 2017-2023
    • Figure 11: Global Market for Beta Blocker Drugs, by Region, 2017-2023
    • Figure 12: Global Market for Calcium Channel Blocker Drugs, 2017-2023
    • Figure 13: Global Market for Calcium Channel Blocker Drugs, by Region, 2017-2023
    • Figure 14: Global Market for Diuretics Drugs, 2017-2023
    • Figure 15: Global Market for Diuretics Drugs, by Region, 2017-2023
    • Figure 16: Global Market for Combination Drugs, 2017-2023
    • Figure 17: Global Market for Combination Drugs, by Region, 2017-2023
    • Figure 18: Global Market for Other Antihypertensive Drugs, 2017-2023
    • Figure 19: Global Market for Other Antihypertensive Drugs, by Region, 2017-2023
    • Figure 20: Global Market Share for Antihypertensive Drugs, by Region, 2017
    • Figure 21: North American Market Share for Antihypertensive Drugs, by Drug Class, 2017
    • Figure 22: North American Market Share for Antihypertensive Drugs, by Country, 2017
    • Figure 23: U.S. Market for Antihypertensive Drugs, 2017-2023
    • Figure 24: Canadian Market for Antihypertensive Drugs, 2017-2023
    • Figure 25: Mexican Market for Antihypertensive Drugs, 2017-2023
    • Figure 26: European Market Share for Antihypertensive Drugs, by Drug Class, 2017
    • Figure 27: European Market Share for Antihypertensive Drugs, by Country, 2017
    • Figure 28: German Market for Antihypertensive Drugs, 2017-2023
    • Figure 29: French Market for Antihypertensive Drugs, 2017-2023
    • Figure 30: U.K. Market for Antihypertensive Drugs, 2017-2023
    • Figure 31: Italian Market for Antihypertensive Drugs, 2017-2023
    • Figure 32: Spanish Market for Antihypertensive Drugs, 2017-2023
    • Figure 33: Rest of Europe Market for Antihypertensive Drugs, 2017-2023
    • Figure 34: Asia-Pacific Market Share for Antihypertensive Drugs, by Drug Class, 2017
    • Figure 35: Asia-Pacific Market Share for Antihypertensive Drugs, by Country, 2017
    • Figure 36: Japanese Market for Antihypertensive Drugs, 2017-2023
    • Figure 37: Chinese Market for Antihypertensive Drugs, 2017-2023
    • Figure 38: Indian Market for Antihypertensive Drugs, 2017-2023
    • Figure 39: Rest of Asia-Pacific Market for Antihypertensive Drugs, 2017-2023
    • Figure 40: South American Market for Antihypertensive Drugs, 2017-2023
    • Figure 41: South American Market Share for Antihypertensive Drugs, by Drug Class, 2017
    • Figure 42: Middle Eastern and African Market for Antihypertensive Drugs, 2017-2023
    • Figure 43: Middle East and African Market Share for Antihypertensive Drugs, by Drug Class, 2017
    • Figure 44: China CFDA Drug Regulatory Approval Process
    • Figure 45: Global Antihypertensive Drug Market Share, by Manufacturer, 2017
    • Figure 46: Novartis AG: Sales Revenue for Co-Diovan/Diovan HCT, 2014-2017
    • Figure 47: Allergan Plc: Annual Revenue, 2013-2017
    • Figure 48: Allergan Plc: Revenue Share, by Business Unit, 2017
    • Figure 49: AstraZeneca Plc: Annual Revenue, 2013-2017
    • Figure 50: AstraZeneca Plc: Revenue Share, by Business Unit, 2017
    • Figure 51: AstraZeneca Plc: Revenue Share, by Region, 2017
    • Figure 52: Bayer AG: Annual Revenue, 2013-2017
    • Figure 53: Bayer AG: Revenue Share, by Region, 2017
    • Figure 54: Boehringer Ingelheim GmbH: Annual Revenue, 2013-2017
    • Figure 55: Boehringer Ingelheim GmbH: Revenue Share, by Region, 2017
    • Figure 56: Daiichi Sankyo Co. Ltd.: Annual Revenue, 2015-2017
    • Figure 57: Gilead Sciences Inc.: Annual Revenue, 2014-2017
    • Figure 58: Johnson & Johnson: Annual Revenue, 2013-2017
    • Figure 59: Johnson & Johnson: Revenue Share, by Region, 2017
    • Figure 60: Johnson & Johnson: Revenue Share, by Business Unit, 2017
    • Figure 61: Novartis AG.: Annual Revenue, 2013-2017
    • Figure 62: Novartis AG: Revenue Share, by Region, 2017
    • Figure 63: Novartis AG: Revenue Share, by Business Segment, 2017
    • Figure 64: Pfizer Inc.: Annual Revenue, 2013-2017
    • Figure 65: Pfizer Inc.: Revenue Share, by Region, 2017
    • Figure 66: Pfizer Inc.: Revenue Share, by Business Segment, 2017
    • Figure 67: Sanofi.: Annual Revenue, 2013-2017
    • Figure 68: Sanofi: Revenue Share, by Region, 2017
    • Figure 69: United Therapeutics Corp: Annual Revenue, 2015-2017